Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs

Journal of Medicinal Chemistry

Volumn 50, Issue 21, 2007, Pages 5103-5108

  Lange, Jos H M ^a   Reinders, Jan Hendrik ^a   Tolboom, Jeroen T B M ^a   Glennon, Jeffrey C ^a   Coolen, Hein K A C ^a   Kruse, Chris G ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [4 (5 FLUORO 1H INDOL 3 YL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL]BUTYL]PHTHALIMIDE; 5 [4 [5 (4 FLUOROPHENYL) 3 PYRIDINYLMETHYL] 1 PIPERAZINYL] 1,4 BENZODIOXAN; 8 [4 [3 (5 FLUORO 1H INDOL 3 YL)PROPYL] 1 PIPERAZINYL] 2 METHYL 1,4 BENZOXAZIN 3(4H) ONE; AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ARTICLE; BINDING AFFINITY; DRUG RECEPTOR BINDING; HUMAN; HYPERPROLACTINEMIA; MONOAMINERGIC SYSTEM; PRINCIPAL COMPONENT ANALYSIS; RECEPTOR BINDING; SCORING SYSTEM; SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BENZOXAZINES; BIOGENIC MONOAMINES; HUMANS; HYPERPROLACTINEMIA; INDOLES; METABOLIC DISEASES; PHTHALIMIDES; PIPERAZINES; PRINCIPAL COMPONENT ANALYSIS; PYRIDINES; RADIOLIGAND ASSAY; RECEPTORS, BIOGENIC AMINE; WEIGHT GAIN;

EID: 35348865625     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070516u     Document Type: Article

References (61)

1. (a) Capuano, B.; Crosby, I. T.; Lloyd, E. J. Schizophrenia: Genesis, receptorology and current therapeutics. Curr. Med. Chem. 2002, 9, 521-548.
2. (b) Mueser, K. T.; McGurk, S. R. Schizophrenia. Lancet 2004, 363, 2063-2072.
3. (a) Sawa, A; Snyder, S. H. Schizophrenia, Diverse approaches to a complex disease. Science 2002, 296, 692-695.
4. (b) Wickelgren, I. A. A route to treating schizophrenia? Science 1998, 281, 1264-1265.
5. Carlsson, A.; Lyndquist, M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. 1963, 20, 140-144.
6. 2 receptors. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27, 1081-1090.
7. (a) Carlsson, A.; Hansson, L. O.; Waters, N.; Carlsson, M. L. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications. Life Sci. 1997, 61, 75-9
8. (b) Carlsson, M. L.; Carlsson, A.; Nilsson, M. Schizophrenia: From dopamine to glutamate and back. Curr. Med. Chem. 2004, 11, 267-277.
9. (a) Farah, A. Atypicality of atypical antipsychotics. J. Clin. Psychiatry 2005, 7, 268-274.
10. (b) Reynolds, G. P. What is an atypical antipsychotic? J. Psychopharmacol. 1997, 11, 195-199.
11. Arnt, J.; Skarsfeldt, M. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacol. 1998, 18, 63-101.
12. (a) Serretti, A.; De Ronchi, D.; Lorenzi, C,; Berardi, D. C. New antipsychotics and schizophrenia: A review on efficacy and side effects. Curr. Med. Chem. 2004, 11, 343-358.
13. (b) De Oliveira, I. R.; Juruena, M. F. Treatment of psychosis: 30 years of progress. J. Clin. Pharm. Ther. 2006, 31, 523-534.
14. (c) Campbell, M.; Young, P. I.; Batemen, D. N. The use of atypical antipsychotics in the management of schizophrenia. Br. J. Pharmacol. 1999, 47, 13-22.
15. 3 dopamine receptor antagonistic activity and limbic selectivity. J. Pharmacol. Exp. Ther. 1997, 280, 73-82.
16. (a) Jarema, M. Atypical antipsychotics in the treatment of mood disorders. Curr. Opin. Psychiatry 2007, 20, 23-29.
17. (b) Buckley, P. F. Second-generation antipsychotic medications in the treatment of mood disorders: Focus on aripiprazole. Drugs Today 2005, 41, 5-11.
18. (a) Keltner, N. L. Metabolic syndrome: Schizophrenia and atypical antipsychotics. Perspect. Psychiatry Care 2006, 42, 204-207.
19. (b) Allison, D. B.; Mentore, J. L.; Heo, M.; Chandler, L. P.; Cappelleri, J. C.; Infante, M. C.; Weiden, P. J. Antipsychotic-induced weight gain; A comprehensive research synthesis. Am. J. Psychiatry 1999, 156, 1686-1696.
20. (c) Newcomer, J. W. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005, 19, 1-93.
21. (d) Koller, E. A.; Doraiswamy, P. M. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002, 22, 841-852.
22. Murphy, B. P.; Chung, Y.; Park, T.; McGorry, P. D. Pharmacological treatment of primary negative symptoms in schizophrenia: A systematic review. Schizophrenia Res. 2006, 88, 5-25.
23. Feenstra, R. W.; de Moes, J.; Hofma, J. J.; Kling, H.; Kuipers, W.; Long, S. K.; Tulp, M. T.; van der Heyden, J. A.; Kruse, C. G. New 1-aryl-4-(biarylmethylene) piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affinities. Bioorg. Med. Chem. Lett. 2001, 11, 2345-2349.
24. 2 receptor antagonism with serotonin reuptake inhibition. Bioorg. Med. Chem Lett. 2003, 13, 405-408.
25. 2 receptor antagonism with potent serotonin reuptake inhibition. J. Med. Chem. 2005, 48, 6855-6869.
26. 1A receptors showing varying degrees of (ant)agonism. Selection of a potential antipsychotic. Chem. Pharm. Bull. 2006, 54, 1326-1330.
27. 1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 2007, 32, 78-94.
28. Grandy, D. K.; Marchionni, M. A.; Makam, H.; Stofko, R. E.; Alfano, M.; Frothingham, L.; Fischer, J. B.; Burke-Howie, K. J.; Bunzow, J. R.; Server, A. C.; Civelli, O. Cloning of the cDNA and gene for a human D2 dopamine receptor. Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9762-9766.
29. 3 receptor expressed in transfected cell lines. Eur. J. Pharmacol. 1994, 266, 79-85.
30. Van, Tol, H. H. M.; Wu, C. M.; Guan, H. C.; Ohara, K.; Bunzow, J. R.; Civelli, O.; Kennedy, J.; Seeman, P.; Niznik, H. B.; Jovanovic, V. Multiple dopamine D4 receptor variants in the human population. Nature 1992, 358, 149-152.
31. Mulheron, J. G.; Casanas, S. J.; Arthur, J. M.; Garnovskaya, M. N.; Gettys, T. W.; Raymond, J. R. Human 5-HT(1A) receptor expressed in insect cells activates endogenous G(o)-like G protein(s). J. Biol. Chem. 1994, 269, 12954-12962.
32. Bonhaus, D. W.; Bach, C.; DeSouza, A.; Salazar, F. H. R.; Matsuoka, B. D.; Zuppan, P.; Chan, H. W.; Eglen, R. M. The pharmacology and distribution of human 5-hydroxytryptamine2B (5-HT(2B)) receptor gene products: Comparison with 5-HT(2A) and 5-HT(2C) receptors. Br. J. Pharmacol. 1995, 115, 622-628.
33. Choi, D. S.; Birraux, G.; Launay, J. M.; Maroteaux, L. The human serotonin 5-HT2B receptor: Pharmacological link between 5-HT2 and 5-HT1D receptors. FEBS Lett. 1994, 352, 393-399.
34. Hope, A. G.; Peters, J. A.; Brown, A. M.; Lambert, J. J.; Blackburn, T. P. Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-A(s)) subunit stably expressed in HEK 293 cells. Br. J. Pharmacol. 1996, 118, 1237-1245.
35. Monsma, F. J.; Shen, Y.; Ward, R. P.; Hamblin, M. W.; Sibley, D. R. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol. Pharmacol. 1993, 43, 320-327.
36. Shen, Y; Monsma, F. J.; Metcalf, M. A.; Jose, P. A.; Hamblin, M. W.; Sibley, D. R. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. J. Biol. Chem. 1993, 268, 18200-18204).
37. Tatsumi, M.; Jansen, K.; Blakely, R. D.; Richelson, E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur. J. Pharmacol. 1999, 368, 277-283.
38. Dorje, F.; Wess, J.; Lambrecht, G.; Tacke, R.; Mutschler, E.; Brann, M. R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 1991, 256, 727-733.
39. Greengrass, P.; Bremner, R. Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptors. Eur. J. Pharmacol. 1979, 55, 323-326.
40. Uhlen, S.; Wikberg, J. E. S. Rat spinal cord α2-adrenoceptors are of the α(2A)-subtype: Comparison with α(2A)- and α(2B)-adrenoceptors in rat spleen, cerebral cortex and kidney using 3H-RX821002 ligand binding. Pharmacol. Toxicol. 1991, 69, 341-350.
41. Dini, S.; Caselli, G. F.; Ferrari, M. P.; Giani, R.; Clavenna, G. Heterogeneity of [3H]-mepyramine binding sites in guinea pig cerebellum and lung. Agents Actions 1991, 33, 181-184.
42. Henrion, R. N-way principal component analysis theory, algorithms and applications. Chemom. Intell. Lab. Syst. 1994, 25, 1-23.
43. (a) Migliavacca, E. Applied introduction to multivariate methods used in drug discovery. Mini-Rev. Med. Chem. 2003, 3, 831-843.
44. (b) Dunn, W. J.; Wold, S.; Martin, Y. C. Structure activity study of β-adrenergic agents using the SIMCA method of pattern recognition. J. Med. Chem. 1978, 21, 922-930.
45. (c) Steindl, T. M.; Crump, C. E.; Hayden, F. G.; Langer, T. Pharmacophore modeling, docking, and principal component analysis based clustering: Combined computer-assisted approaches to identify new inhibitors of the human rhinovirus coat protein. J. Med. Chem. 2005, 48, 6250-6260.
46. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 2001, 158, 360-369.
47. 2 receptors with clozapine: Differentiation from other atypical antipsychotics. Am. J. Psychiatry 2004, 161, 1620-1625.
48. Kim, S. F.; Huang, A. S.; Snowman, A. M.; Teuscher, C.; Snyder, S. H. Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc. Natl. Acad. Sci. USA. 2007, 104, 3456-3459.
49. Jibson, M. D.; Tandon, R. New atypical antipsychotic medications. J. Psychiatr. Res. 1998, 32, 215-228.
50. Weiden, P. J. EPS profiles: The atypical antipsychotics are not all the same. J. Psychiatr. Pract. 2007, 13, 13-24.
51. Lublin, H.; Eberhard, J.; Levander, S. Current therapy issues and unmet clinical needs in the treatment of schizophrenia: A review of the new generation antipsychotics. Int. Clin. Psychopharmacol. 2005, 20, 183-198.
52. Haddad, P. M.; Wieck, A. Antipsychotic-induced hyperprolactinaemia; Mechanisms, clinical features and management. Drugs 2004, 64, 2292-2314.
53. (a) Hamner, M. B.; Arana, G. W. Hyperprolactinaemia in antipsychotic-treated patients. CNS Drugs 1998, 10, 209-222.
54. (b) Hamner, M. The effects of atypical antipsychotics on serum prolactin levels. Ann. Clin. Psychiatry 2002, 14, 163-173.
55. Naber, D.; Lambert, M. Aripiprazole: a new atypical antipsychotic witt different pharmacological mechanism. Progr. Neuro-Psychopharmacol. Biol. Psychiatry 2004, 28, 1213-1219.
56. DeLeon, A.; Patel, N. C.; Crismon, M. L. Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin. Ther. 2004, 26, 649-666.
57. Lieberman, J. A. Dopamine partial agonists: A new class of antipsychotic. CNS Drugs 2004, 18, 251-267.
58. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
59. Lawless, J. F. Statistical models and methods for lifetime data; John Wiley & Sons: New York, 1982; pp 220-237.
60. Johnson, N. L.; Kotz, S. Continuous univariate distributions; Houghton Mifflin Company: Boston, MA, 1970; Vol. 1, pp 81-83.
61. SAS Institute, Inc. SAS OnlineDoc, version 8; SAS Institute, Inc.: Cary, NC, 1999.